Cargando…

Patient-reported outcomes in adoptive cell-therapy trials: mind the gap

Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghisoni, Eleonora, Morotti, Matteo, Colomer-Lahiguera, Sara, Eicher, Manuela, Coukos, George, Trueb, Lionel, Di Maio, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743398/
https://www.ncbi.nlm.nih.gov/pubmed/36600604
http://dx.doi.org/10.1136/jitc-2022-006082
_version_ 1784848718319583232
author Ghisoni, Eleonora
Morotti, Matteo
Colomer-Lahiguera, Sara
Eicher, Manuela
Coukos, George
Trueb, Lionel
Di Maio, Massimo
author_facet Ghisoni, Eleonora
Morotti, Matteo
Colomer-Lahiguera, Sara
Eicher, Manuela
Coukos, George
Trueb, Lionel
Di Maio, Massimo
author_sort Ghisoni, Eleonora
collection PubMed
description Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials.
format Online
Article
Text
id pubmed-9743398
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97433982022-12-13 Patient-reported outcomes in adoptive cell-therapy trials: mind the gap Ghisoni, Eleonora Morotti, Matteo Colomer-Lahiguera, Sara Eicher, Manuela Coukos, George Trueb, Lionel Di Maio, Massimo J Immunother Cancer Commentary Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials. BMJ Publishing Group 2022-12-09 /pmc/articles/PMC9743398/ /pubmed/36600604 http://dx.doi.org/10.1136/jitc-2022-006082 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Ghisoni, Eleonora
Morotti, Matteo
Colomer-Lahiguera, Sara
Eicher, Manuela
Coukos, George
Trueb, Lionel
Di Maio, Massimo
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
title Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
title_full Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
title_fullStr Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
title_full_unstemmed Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
title_short Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
title_sort patient-reported outcomes in adoptive cell-therapy trials: mind the gap
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743398/
https://www.ncbi.nlm.nih.gov/pubmed/36600604
http://dx.doi.org/10.1136/jitc-2022-006082
work_keys_str_mv AT ghisonieleonora patientreportedoutcomesinadoptivecelltherapytrialsmindthegap
AT morottimatteo patientreportedoutcomesinadoptivecelltherapytrialsmindthegap
AT colomerlahiguerasara patientreportedoutcomesinadoptivecelltherapytrialsmindthegap
AT eichermanuela patientreportedoutcomesinadoptivecelltherapytrialsmindthegap
AT coukosgeorge patientreportedoutcomesinadoptivecelltherapytrialsmindthegap
AT trueblionel patientreportedoutcomesinadoptivecelltherapytrialsmindthegap
AT dimaiomassimo patientreportedoutcomesinadoptivecelltherapytrialsmindthegap